Adaptive Biotechnologies (NASDAQ:ADPT) Director Peter Neupert Sells 124,690 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Peter Neupert sold 124,690 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the sale, the director directly owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. This represents a 48.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $25.49 on Thursday. The company has a market capitalization of $4.07 billion, a PE ratio of -62.17 and a beta of 2.08. Adaptive Biotechnologies Corporation has a one year low of $12.00 and a one year high of $26.16. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The company’s fifty day moving average price is $21.75 and its 200 day moving average price is $17.24.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm’s revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) earnings per share. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ADPT shares. Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, Guggenheim increased their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Allworth Financial LP acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth about $35,000. Caitong International Asset Management Co. Ltd bought a new stake in Adaptive Biotechnologies during the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC grew its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.